Bid Banana
PricingBid helpAPILog inStart free trial
Log inStart free trial

Learn more

  • Washington guideWashington Bids and Bidding Guide
  • Healthcare RFPsHealthcare and Medical Services Bids and Bidding Guide
More healthcare and medical services bids →Must-win bid? Bring in The Bid Lab →
Bid Banana
SearchPricingBid helpBrowse bidsAPISupportFAQPrivacy PolicyTerms of UseAI Use Policy

This website and its content is copyright of The Bid Lab © 2026. The Bid Lab is a trademark of Bid Lab, LLC. All rights reserved.

  1. Bid Banana
  2. ›Closed bids
  3. ›Washington
  4. ›Healthcare and Medical Services
  5. ›Expedited Drug Analysis Program

Awarded contract·Snohomish County·Washington

Expedited Drug Analysis Program

Won by Cordant Health Solutions$348kAwarded 7/1/2024Single Award
Contract source

Awarded vendors

  • Cordant Health Solutions

Description

This contract provides comprehensive drug‑and‑alcohol testing and specimen‑collection services for Snohomish County’s recovery courts, detention, and probation programs. Cordant Health Solutions will operate collection sites, maintain SAMHSA‑certified laboratory capabilities, and deliver results via a web‑based platform, adhering to strict chain‑of‑custody and staffing requirements. The agreement is a fixed‑price, unit‑price arrangement with a maximum contract value of $348,000 for the 2024‑2025 term, and includes provisions for invoicing, electronic payment, and potential extensions. • Scope: Observed urine (and optional oral‑fluid) collection, random scheduling, 24/7 notification line, result reporting within 24‑48 h (negatives) or 48‑96 h (positives). • Requirements: SAMHSA‑certified lab, male + female collectors on‑site, daily specimen transport, detailed reporting, and extensive insurance and indemnification obligations. • Financials: Tiered per‑specimen fees (≈$68 down to $17.76) plus per‑panel testing fees; invoicing by the 10th of the following month; e‑Payable processing within 7 days.

Attached files

Key dates

Bids closed
5/9/2024
Intent to award
7/1/2024
Awarded
7/1/2024
Starts
1/1/2024
Ends
12/31/2025Renews
Duration
2 years

Last updated

Details

Award type
Single Award
Procurement
Full and Open Competition
Industry
Healthcare and Medical Services
NAICS
621511
Solicitation №
RFP-24-015RB

Contract value

$348,000

The contract explicitly states a maximum contract value of $348,000 for the initial 24‑month term. This figure represents the ceiling spend based on tiered per‑specimen fees and testing panel charges. Because the agreement allows for up to two additional two‑year extensions, the total potential outlay could reach approximately $1,044,000 if the full value is realized each term, but the guaranteed commitment for the base period is $348,000.

AI estimate from the award documents

Similar open opportunities

Matched by Bid Banana AI™

U.S. National Institutes of Health·United States of America

Top match · 64%

Mechanism for Time-Sensitive Substance Use Research (R21 Clinical Trial Optional)

Closes 9/9/2027Opened 9/20/2024

U.S. National Science Foundation·United States of America

64% match

Analysis

Rolling / TBD closeOpened 3/17/2020

U.S. National Institutes of Health·United States of America

64% match

Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)

Closes 12/3/2027Opened 12/5/2024

City of Tulsa·Oklahoma

64% match

Drug Testing Lab Services

Closes 11/4/2026Opened 10/10/2026

U.S. National Institutes of Health·United States of America

63% match

Accelerating Discovery through Partnered Research with All of Us to Analyze Participant Biospecimens (X01 Clinical Trial Not Allowed)

Closes 3/1/2027Opened 1/8/2026

City of El Paso·Texas

63% match

Drug Testing and Alcohol Screening

Closes 11/4/2026Opened 10/6/2026

U.S. Food and Drug Administration·United States of America

62% match

Identification and Evaluation of Possible Approaches to Addressing Nitrosamine Impurities in Drugs (U01)

Rolling / TBD closeOpened 11/24/2023

U.S. Food and Drug Administration·United States of America

61% match

Synthesis and Biological Activity Assessment of Different Diastereomers in siRNA Drug LEQVIO (Inclisiran) (U01) Clinical Trial Not Allowed

Rolling / TBD closeOpened 11/24/2023

U.S. National Institutes of Health·United States of America

61% match

Accelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Not Allowed)

Closes 12/3/2027Opened 12/5/2024

Health, NYS Dept. of·New York

61% match

Preferred Drug Program / Pharmacy Benefits Management C020463 X-12

Rolling / TBD closeOpened 10/16/2026

City of El Paso·Texas

61% match

Drug Testing and Alcohol Screening

Closes 11/4/2026Opened 10/6/2026

U.S. Department Of Health And Human Services·United States of America

61% match

Synthesis and Distribution of Drugs of Abuse and Related Compounds

Closes 11/20/2026Opened 10/29/2026

U.S. Department Of Health And Human Services·United States of America

61% match

Synthesis and Distribution of Drugs of Abuse and Related Compounds

Closes 11/20/2026Opened 10/29/2026

U.S. Department Of Defense·Maryland

61% match

Generative Unconstrained Intelligence Drug Engineering (GUIDE) collaboration between U.S. interagency, academic and industry partners

Closes 10/18/2028Opened 10/18/2024

City of Colorado Springs·Colorado

61% match

Drug-Free Workplace Program

Closes 11/6/2026Opened 10/23/2026

U.S. Food and Drug Administration·United States of America

61% match

NARMS Cooperative Agreement Program to Strengthen Antibiotic Resistance Surveillance in Retail Food Specimens

Closes 4/1/2027Opened 7/11/2025

Iowa State University·Iowa

61% match

Blood Spot and Dried Urine Testing

Closes 11/6/2026Opened 10/23/2026

U.S. Department Of Health And Human Services·Maryland

60% match

NIA:Non-Competitive Combined Synopsis/Solicitation

Closes 11/6/2026Opened 10/28/2026

Texas Dept Of State Health Services·Texas

60% match

Pharmacy Drug Benefits

Closes 11/19/2026Opened 10/21/2026

U.S. Food and Drug Administration·United States of America

60% match

Utilizing Real-World Data and Algorithmic Analyses to Assess Post-Market Clinical Outcomes in Patients Switching Amongst Therapeutically Equivalent Complex Generic Drug Products and Reference Listed Drugs (U01) Clinical Trial Not Allowed

Rolling / TBD closeOpened 11/24/2023

Florida Department of Corrections (FDC)·Florida

60% match

Laboratory Analysis on Water Treatment Plants, Wastewater Treatment Plants, and Groundwater Monitor

Closes 8/30/2027Opened 9/30/2026

Mississippi

60% match

Drug Testing System – Request for Proposal

Closes 11/5/2026Opened 10/30/2026

University of Texas MD Anderson Cancer Center·Texas

60% match

Discovery and Development of Small Molecules and Biologic Therapies RFP

Closes 12/9/2026Opened 10/30/2026